IRVINE, Calif., July 24, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Asanko Gold Inc. (“Asanko” or the “Company”) (NYSE MKT:AKG). Investors who purchased or otherwise acquired Asanko shares from October 24, 2014 through May 31, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm before July 31, 2017, the lead plaintiff motion deadline.
If you purchased Asanko shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Asanko made false and/or misleading statements and/or failed to disclose: that the Company’s Mineral Resource Estimates are flawed; that some of Asanko’s resources models exhibit signs that they have been “smeared,” which would cause estimates of their ore contents to be inflated; and that as a result of the above, Asanko’s public statements were materially false and misleading at all relevant times. When this news reached the public, Asanko’s stock price fell materially, which caused investors harm.
If you want to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]


Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Italy Fines Apple €98.6 Million Over App Store Dominance
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
FDA Approves Mitapivat for Anemia in Thalassemia Patients
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 



